Published June, 2023
Patients with symptomatic heart failure (HF) and previous heart failure hospitalization (HFH) were treated with hemodynamic-guided HF management using a wireless pulmonary artery pressure (PAP) sensor which resulted in reduced HFH.
A new study published in JACC: Heart Failure demonstrates consistent effects of hemodynamic-guided HF management across enrollment strata in GUIDE-HF support consideration of hemodynamic monitoring in the expanded group of patients with chronic HF and elevated natriuretic peptides without recent HFH. Ochsner principal investigator Selim Krim, MD, Director, Advanced HF Research Section was co-author on the publication.
Ochsner was a top enroller (2nd in nation) for the randomized portion of this trial with enrollment efforts involving clinical research coordinators Kelly Boudet and Jessica Henry.
Following the trial results, the FDA and CMS expanded the indication of the CardioMEMS device, and it is now commercially approved for patients with heart failure (HFpEF and HFrEF) with NYHA class II-III symptoms and either a previous HF admission or elevated BNP.
Ochsner’s Remote Monitoring Program using the CardioMEMS allows clinicians to stabilize PA pressures by proactively managing medications and other treatment options while also providing an early indication of worsening HF, reducing HF admissions by 30-50%.
Ochsner Cardiology at OMC Jefferson Highway campus has implanted approximately 150 CARDIOMEMS devices and continues to grow with device implants now available at Ochsner West Bank, St. Tammany, and Baton Rouge campuses.
